Accès ouvert
2025
article
OpenAlex
Greta Catani, Oriol Mirallas, Vicky Sánchez-Pérez, Paolo Giovanni Nuciforo et autres
Immune checkpoint inhibitors have revolutionized the treatment of solid tumors; however, their clinical efficacy remains limited to a subset of patients. Novel immunotherapy agents are being investigated in phase I clinical trials, with an increasing focus on biomarker selection strategies to optimize …
es, ar, us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
D. Morchón Araujo, Greta Catani, Oriol Mirallas, Giulia Pretelli et autres
Immunotherapy has significantly changed the treatment paradigm for solid tumors, with immune checkpoint inhibitors now established in the management of many malignancies. Despite initial success, durable responses remain limited to a subset of patients, often less than 30%, due to both intrinsic …
es, ar
(code pays fourni par la source)
2022
conference-abstract
OpenAlex
Elena Garralda, Alonso Guzman, Juanita Suzanne Lopez, Vicky Sánchez-Pérez et autres
Abstract Developing a safe and effective non-alpha IL-2R agonist to enhance the numbers and activation status of immune effector cells for the treatment of cancer has remained an elusive goal since the initial approval of Interleukin-2 (IL-2). ANV419 comprises an antibody specific …
es, gb, ch
(code pays fourni par la source)